...
首页> 外文期刊>Metabolomics >Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study)
【24h】

Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study)

机译:使用基于ms的代谢组学发现糖尿病肾脏疾病的早期生物标记物(FinnDiane研究)

获取原文
           

摘要

Diabetic kidney disease (DKD) is a devastating complication that affects an estimated third of patients with type 1 diabetes mellitus (DM). There is no cure once the disease is diagnosed, but early treatment at a sub-clinical stage can prevent or at least halt the progression. DKD is clinically diagnosed as abnormally high urinary albumin excretion rate (AER). We hypothesize that subtle changes in the urine metabolome precede the clinically significant rise in AER. To test this, 52 type 1 diabetic patients were recruited by the FinnDiane study that had normal AER (normoalbuminuric). After an average of 5.5 years of follow-up half of the subjects (26) progressed from normal AER to microalbuminuria or DKD (macroalbuminuria), the other half remained normoalbuminuric. The objective of this study is to discover urinary biomarkers that differentiate the progressive form of albuminuria from non-progressive form of albuminuria in humans. Metabolite profiles of baseline 24 h urine samples were obtained by gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) to detect potential early indicators of pathological changes. Multivariate logistic regression modeling of the metabolomics data resulted in a profile of metabolites that separated those patients that progressed from normoalbuminuric AER to microalbuminuric AER from those patients that maintained normoalbuminuric AER with an accuracy of 75% and a precision of 73%. As this data and samples are from an actual patient population and as such, gathered within a less controlled environment it is striking to see that within this profile a number of metabolites (identified as early indicators) have been associated with DKD already in literature, but also that new candidate biomarkers were found. The discriminating metabolites included acyl-carnitines, acyl-glycines and metabolites related to tryptophan metabolism. We found candidate biomarkers that were univariately significant different. This study demonstrates the potential of multivariate data analysis and metabolomics in the field of diabetic complications, and suggests several metabolic pathways relevant for further biological studies.
机译:糖尿病肾病(DKD)是一种破坏性并发症,估计会影响三分之一的1型糖尿病(DM)患者。一旦诊断出疾病,就无法治愈,但是亚临床阶段的早期治疗可以预防或至少阻止疾病的发展。 DKD在临床上被诊断为尿白蛋白排泄率(AER)异常高。我们假设尿中代谢组的细微变化先于AER的临床显着上升。为了对此进行测试,FinnDiane研究招募了52名AER(正常白蛋白尿)正常的1型糖尿病患者。在平均5.5年的随访之后,一半的受试者(26)从正常AER进展为微量白蛋白尿或DKD(大白蛋白尿),另一半则保持正常白蛋白尿。这项研究的目的是发现在人类中区分蛋白尿进行性和非蛋白尿的尿液生物标志物。通过气相色谱-质谱(GC-MS)和液相色谱-质谱(LC-MS)获得基线24小时尿液样本的代谢物谱,以检测潜在的病理变化早期指标。代谢组学数据的多元logistic回归建模产生了一种代谢产物图谱,这些代谢产物将那些从正常白蛋白AER演变为微量白蛋白AER的患者与那些维持正常白蛋白AER的患者分开,准确度为75%,准确度为73%。由于这些数据和样本均来自实际的患者人群,因此是在控制较少的环境中收集的,令人惊讶的是,在文献中已经发现许多代谢物(已确定为早期指标)已经与DKD相关联,但是还发现了新的候选生物标记。区分代谢物包括酰基肉碱,酰基甘氨酸和与色氨酸代谢有关的代谢物。我们发现候选生物标记具有单变量显着性差异。这项研究证明了在糖尿病并发症领域进行多元数据分析和代谢组学的潜力,并提出了与进一步生物学研究相关的几种代谢途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号